|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1617181920212223242526...4041» |
- Enrollment closed: Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=1118, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab in Systemic Sclerosis (clinicaltrials.gov) - Jul 28, 2014
P2/3, N=90, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Oct 2016
- Uplizna (inebilizumab) / Horizon Therapeutics, Mitsubishi Tanabe
Enrollment closed, Trial primary completion date: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 28, 2014
P1, N=28, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Jun 2014 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015
- | NurOwn (MSC-NTF) / BrainStorm Cell Therap
Enrollment open: NurOwn: Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS (clinicaltrials.gov) - Jul 27, 2014
P2, N=48, Recruiting, Sponsor: Brainstorm-Cell Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Feb 2015 Not yet recruiting --> Recruiting
- pepinemab (VX15) / Vaccinex
Enrollment closed, Trial primary completion date: Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS (clinicaltrials.gov) - Jul 27, 2014
P1, N=50, Active, not recruiting, Sponsor: Vaccinex Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2015
- Clinical: MFP: Mobility Enhancing Nursing Intervention (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=140, Completed, Sponsor: Zurich University of Applied Sciences
- teriflunomide / Generic mfg.
Enrollment closed: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jul 23, 2014
P1, N=12, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2015 Recruiting --> Active, not recruiting
- Enrollment open, Trial initiation date, Trial primary completion date: SIAMMS-II: Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (clinicaltrials.gov) - Jul 21, 2014
P1, N=6, Recruiting, Sponsor: North Bristol NHS Trust
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jan 2014 | Trial primary completion date: Sep 2015 --> Sep 2016
- |||| dalfampridine / Generic mfg.
Trial completion: Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (clinicaltrials.gov) - Jul 21, 2014
P2, N=132, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting | Initiation date: Oct 2013 --> Jan 2014 | Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed
- Trial primary completion date: Evaluation of Coagulation in Multiple Sclerosis (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=100, Recruiting, Sponsor: Bastyr University
Active, not recruiting --> Completed Trial primary completion date: Jun 2013 --> Apr 2015
- Trial primary completion date: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Jul 17, 2014
P1, N=30, Recruiting, Sponsor: GE Healthcare
Trial primary completion date: Jun 2013 --> Apr 2015 Trial primary completion date: Sep 2014 --> Dec 2015
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P1 trial: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (clinicaltrials.gov) - Jul 17, 2014
P1, N=0, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||| ambrisentan / Generic mfg.
Enrollment closed, Trial primary completion date: ATPAHSS: A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (clinicaltrials.gov) - Jul 17, 2014
P4, N=63, Active, not recruiting, Sponsor: United Therapeutics
Trial primary completion date: Sep 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Nov 2014
- ||||||| arbaclofen placarbil (XP 19986) / Arbor Pharma, Indivior
Trial completion, Trial primary completion date: Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 15, 2014
P3, N=218, Completed, Sponsor: XenoPort, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2013
- Enrollment closed: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 15, 2014
P1, N=20, Active, not recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2013 Recruiting --> Active, not recruiting
- || Enrollment change, Trial primary completion date: NEO: An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=254, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting N=154 --> 254 | Trial primary completion date: Oct 2012 --> Oct 2014
- teriflunomide / Generic mfg.
Trial primary completion date: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=50, Recruiting, Sponsor: University at Buffalo
N=154 --> 254 | Trial primary completion date: Oct 2012 --> Oct 2014 Trial primary completion date: Jun 2014 --> Nov 2014
- || Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date, Adherence: MEASURE: Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=198, Completed, Sponsor: Merck KGaA
Trial primary completion date: Jun 2014 --> Nov 2014 Trial primary completion date: Jul 2014 --> Apr 2014
- HEOR: PDMSLac: Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=39, Not yet recruiting, Sponsor: Florida State University
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Evaluation of Brain Atrophy in CIS Patients on Avonex (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=180, Completed, Sponsor: University at Buffalo
Trial primary completion date: Jul 2014 --> Apr 2014 Active, not recruiting --> Completed
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Trial primary completion date, Adherence: MEASURE: Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=198, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Apr 2014
- Trial termination: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 8, 2014
P2, N=3, Terminated, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Apr 2014 Recruiting --> Terminated; Poor recruitment
- Enrollment change, Trial termination: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 8, 2014
P2, N=3, Terminated, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
Recruiting --> Terminated; Poor recruitment N=50 --> 3 | Recruiting --> Terminated; Poor recruitment
- Biomarker, Trial primary completion date: MIRSLA: Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
N=50 --> 3 | Recruiting --> Terminated; Poor recruitment Trial primary completion date: Nov 2014 --> Jun 2015
- Trial primary completion date: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Nov 2014 --> Jun 2015 Trial primary completion date: Feb 2015 --> Dec 2015
- Biomarker, Trial initiation date: MIRSLA: Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Feb 2015 --> Dec 2015 Initiation date: Nov 2013 --> Jun 2014
- Biomarker, Enrollment open, Trial initiation date, Trial primary completion date: MIRSLA: Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Initiation date: Nov 2013 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Nov 2013 --> Jun 2014 | Trial primary completion date: Nov 2014 --> Jun 2015
- || Trial primary completion date: REACTIV: Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=75, Recruiting, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Recruiting | Initiation date: Nov 2013 --> Jun 2014 | Trial primary completion date: Nov 2014 --> Jun 2015 Trial primary completion date: Apr 2014 --> Sep 2014
- ||| Betaseron (IFN-β-1b) / Bayer
Enrollment open, Adherence: BETAEVAL: BAY86-5046 (Betaseron), Non Interventional Studies (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=150, Recruiting, Sponsor: Bayer
Trial primary completion date: Apr 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- || Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P2, N=102, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2013 --> Nov 2014
- Trial primary completion date: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=16, Completed, Sponsor: University of Florida
Trial primary completion date: Sep 2013 --> Nov 2014 Trial primary completion date: Dec 2013 --> Jun 2012
- Enrollment change: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=16, Completed, Sponsor: University of Florida
Trial primary completion date: Dec 2013 --> Jun 2012 N=20 --> 16
- | Tysabri (natalizumab) / Biogen, Royalty
Phase classification: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P2, N=102, Active, not recruiting, Sponsor: Biogen Idec
N=20 --> 16 Phase classification: P=N/A --> P2
- Enrollment open: Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=50, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting
- Biomarker, Enrollment open: Neuroretinal Biomarkers in Neurodegenerative Diseases (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=80, Recruiting, Sponsor: University of Edinburgh
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Biomarker, Enrollment closed: Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Phase classification, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P2, N=102, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | Trial primary completion date: Sep 2013 --> Nov 2014
- | Trial completion, Enrollment change, Trial primary completion date: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=16, Completed, Sponsor: University of Florida
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | Trial primary completion date: Sep 2013 --> Nov 2014 Active, not recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Dec 2013 --> Jun 2012
- Trial completion: Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS (clinicaltrials.gov) - Jun 27, 2014
P1, N=24, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Dec 2013 --> Jun 2012 Active, not recruiting --> Completed
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: RELIEF: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 26, 2014
P4, N=218, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial: Developing and Testing a Comprehensive MS Spasticity Management Program (clinicaltrials.gov) - Jun 24, 2014
P2, N=50, Not yet recruiting, Sponsor: Department of Veterans Affairs
- Enrollment closed: FlexToBa for People With Multiple Sclerosis (clinicaltrials.gov) - Jun 24, 2014
P1, N=60, Active, not recruiting, Sponsor: University of Illinois at Urbana-Champaign
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Copaxone 3TW (glatiramer acetate three times a week) / Teva
Trial completion: Safety and Tolerability of Glatiramer Acetate (clinicaltrials.gov) - Jun 24, 2014
P3, N=210, Completed, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Rebif (human IFN-?-1a) / EMD Serono
Trial primary completion date, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=306, Active, not recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jul 2015
- || Rebif (human IFN-?-1a) / EMD Serono
Enrollment closed, Trial primary completion date, Adherence: EMR 200136-567: Adherence Trial With MS LifeLines (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=306, Active, not recruiting, Sponsor: EMD Serono
Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- Trial primary completion date: An In-home Study of Brain Computer Interfaces (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=6, Enrolling by invitation, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Jan 2012 --> Aug 2015
- Trial primary completion date: P300 Brain Computer Interface Keyboard to Operate Assistive Technology (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=72, Completed, Sponsor: University of Michigan
Trial primary completion date: Jan 2012 --> Aug 2015 Trial primary completion date: May 2009 --> May 2012
- Trial initiation date: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Jun 19, 2014
P2, N=80, Not yet recruiting, Sponsor: Academic MS Center Limburg
Trial primary completion date: May 2009 --> May 2012 Initiation date: May 2014 --> Aug 2014
- Enrollment change: A P300 Brain Computer Interface to Operate Power Wheelchair Tilt (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=16, Completed, Sponsor: University of Michigan
Initiation date: May 2014 --> Aug 2014 N=48 --> 16
- Enrollment change, Trial primary completion date: P300 Brain Computer Interface Keyboard to Operate Assistive Technology (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=72, Completed, Sponsor: University of Michigan
N=48 --> 16 N=158 --> 72 | Trial primary completion date: May 2009 --> May 2012